Scholarlink

<p>Neuroblastoma is the most common extracranial solid tumor in children. The prognosis for high-risk disease remains poor despite multimodal therapy, including chemotherapy, surgical resection, radiotherapy, and autologous stem-cell transplantation. Immunotherapy has improved outcomes remarkably, particularly using anti-GD2 monoclonal antibodies, which are now established as standard maintenance therapy. Combination regimens of cytokines and isotretinoin have enhanced survival, and chemo-immunotherapy has demonstrated superior response rates in relapsed/refractory settings. The aim of treatment with next-generation antibodies, such as humanized or Fc-engineered formats, is to reduce toxicity and improve efficacy. GD2-based vaccines and cellular therapies, including CAR-T cells, NK/NKT cell therapy, and bispecific antibody-armed T cells, have shown promising activity, particularly for minimal residual disease. However, challenges such as GD2 downregulation, an immunosuppressive tumor microenvironment, and manufacturing constraints persist. Future strategies may involve multimodal immunotherapy integrating antibodies, vaccines, and cellular platforms with precise patient selection and microenvironment modulation. Immunotherapy is reshaping neuroblastoma treatment, with the potential to achieve both deeper remission and long-term disease control.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The role of immunotherapy in the treatment of neuroblastoma

  • 期刊论文

  • 发表日期：

    2026年5月22日

查看全文
  • Naonori Kawakubo,
  • Junnosuke Maniwa,
  • Yoshiki Yamaguchi,
  • Michiko Ueda,
  • Yuko Hino,
  • Amane Kamouchi,
  • Kenta Ishimoto,
  • Masahiro Fukuhara,
  • Yoshiaki Takahashi,
  • Yukihiro Toriigahara,
  • Atsuhisa Fukuta,
  • Koichiro Yoshimaru,
  • Kouji Nagata,
  • Junko Miyata,
  • Toshiharu Matsuura,
  • Tatsuro Tajiri

摘要

Neuroblastoma is the most common extracranial solid tumor in children. The prognosis for high-risk disease remains poor despite multimodal therapy, including chemotherapy, surgical resection, radiotherapy, and autologous stem-cell transplantation. Immunotherapy has improved outcomes remarkably, particularly using anti-GD2 monoclonal antibodies, which are now established as standard maintenance therapy. Combination regimens of cytokines and isotretinoin have enhanced survival, and chemo-immunotherapy has demonstrated superior response rates in relapsed/refractory settings. The aim of treatment with next-generation antibodies, such as humanized or Fc-engineered formats, is to reduce toxicity and improve efficacy. GD2-based vaccines and cellular therapies, including CAR-T cells, NK/NKT cell therapy, and bispecific antibody-armed T cells, have shown promising activity, particularly for minimal residual disease. However, challenges such as GD2 downregulation, an immunosuppressive tumor microenvironment, and manufacturing constraints persist. Future strategies may involve multimodal immunotherapy integrating antibodies, vaccines, and cellular platforms with precise patient selection and microenvironment modulation. Immunotherapy is reshaping neuroblastoma treatment, with the potential to achieve both deeper remission and long-term disease control.